PortalPublikationenGene expression analysis identifies potential biomarkers of ...

Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Standard

Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. / Hummel, Trent R; Jessen, Walter J; Miller, Shyra J; Kluwe, Lan; Mautner, Viktor Felix; Wallace, Margaret R; Lázaro, Conxi; Page, Grier P; Worley, Paul F; Aronow, Bruce J; Schorry, Elizabeth K; Ratner, Nancy.

in: CLIN CANCER RES, Jahrgang 16, Nr. 20, 20, 2010, S. 5048-5057.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hummel, TR, Jessen, WJ, Miller, SJ, Kluwe, L, Mautner, VF, Wallace, MR, Lázaro, C, Page, GP, Worley, PF, Aronow, BJ, Schorry, EK & Ratner, N 2010, 'Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.', CLIN CANCER RES, Jg. 16, Nr. 20, 20, S. 5048-5057. <http://www.ncbi.nlm.nih.gov/pubmed/20739432?dopt=Citation>

APA

Hummel, T. R., Jessen, W. J., Miller, S. J., Kluwe, L., Mautner, V. F., Wallace, M. R., Lázaro, C., Page, G. P., Worley, P. F., Aronow, B. J., Schorry, E. K., & Ratner, N. (2010). Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. CLIN CANCER RES, 16(20), 5048-5057. [20]. http://www.ncbi.nlm.nih.gov/pubmed/20739432?dopt=Citation

Vancouver

Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR et al. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. CLIN CANCER RES. 2010;16(20):5048-5057. 20.

Bibtex

@article{faeb3ee7114b4fd58dfaf8d7015e8e92,
title = "Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.",
abstract = "Plexiform neurofibromas (pNF) are Schwann cell tumors found in a third of individuals with neurofibromatosis type 1 (NF1). pNF can undergo transformation to malignant peripheral nerve sheath tumors (MPNST). There are no identified serum biomarkers of pNF tumor burden or transformation to MPNST. Serum biomarkers would be useful to verify NF1 diagnosis, monitor tumor burden, and/or detect transformation.",
author = "Hummel, {Trent R} and Jessen, {Walter J} and Miller, {Shyra J} and Lan Kluwe and Mautner, {Viktor Felix} and Wallace, {Margaret R} and Conxi L{\'a}zaro and Page, {Grier P} and Worley, {Paul F} and Aronow, {Bruce J} and Schorry, {Elizabeth K} and Nancy Ratner",
year = "2010",
language = "Deutsch",
volume = "16",
pages = "5048--5057",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

RIS

TY - JOUR

T1 - Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

AU - Hummel, Trent R

AU - Jessen, Walter J

AU - Miller, Shyra J

AU - Kluwe, Lan

AU - Mautner, Viktor Felix

AU - Wallace, Margaret R

AU - Lázaro, Conxi

AU - Page, Grier P

AU - Worley, Paul F

AU - Aronow, Bruce J

AU - Schorry, Elizabeth K

AU - Ratner, Nancy

PY - 2010

Y1 - 2010

N2 - Plexiform neurofibromas (pNF) are Schwann cell tumors found in a third of individuals with neurofibromatosis type 1 (NF1). pNF can undergo transformation to malignant peripheral nerve sheath tumors (MPNST). There are no identified serum biomarkers of pNF tumor burden or transformation to MPNST. Serum biomarkers would be useful to verify NF1 diagnosis, monitor tumor burden, and/or detect transformation.

AB - Plexiform neurofibromas (pNF) are Schwann cell tumors found in a third of individuals with neurofibromatosis type 1 (NF1). pNF can undergo transformation to malignant peripheral nerve sheath tumors (MPNST). There are no identified serum biomarkers of pNF tumor burden or transformation to MPNST. Serum biomarkers would be useful to verify NF1 diagnosis, monitor tumor burden, and/or detect transformation.

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 5048

EP - 5057

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 20

M1 - 20

ER -